Patents by Inventor Todd Fields

Todd Fields has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP RECEPTOR AGONIST COMPOUNDS
    Publication number: 20260091048
    Abstract: The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.
    Type: Application
    Filed: July 31, 2025
    Publication date: April 2, 2026
    Inventors: Jolie Anne BASTIAN, Thomas James BEAUCHAMP, Douglas Carl BEHENNA, Maria del Pilar BUTELER, Rachel Katherine CHAMBERS, Jiehao CHEN, Zhaogen CHEN, Timothy Barrett DURHAM, Fortune Otuko DZEAGU, Todd FIELDS, Patric James HAHN, Erik James HEMBRE, Youming HUANG, Steven Lee KUKLISH, Jose Eduardo LOPEZ GARCIA, Ethan Lindsay MAGNO, Maxwell Johnson MOORE, Paul Vincent RUCKER, Daniel Copley SCHMITT, Daniel Aaron STRASSFELD, Lewis Robin VIDLER, Gaiying ZHAO
  • RXFP1 RECEPTOR AGONISTS
    Publication number: 20250197413
    Abstract: The present invention provides compounds of the formula: wherein Ring A, R1, R2, and R3 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cardiovascular, pulmonary and/or renal conditions, diseases and/or disorders.
    Type: Application
    Filed: December 13, 2024
    Publication date: June 19, 2025
    Inventors: Erin ANDERSON, Todd FIELDS, Autumn Rose FLYNN, Megan MCKENNEY HALL, Richard Duane JOHNSTON, Jason Eric LAMAR, Christopher MAYNE, Elizabeth MCFADDIN, Andrew METCALF, Tarek SAMMAKIA, Zhicheng SUN
  • GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
    Publication number: 20250002482
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: September 9, 2024
    Publication date: January 2, 2025
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS
    Publication number: 20240343740
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: May 19, 2022
    Publication date: October 17, 2024
    Inventors: Francisco Javier AGEJAS CHICHARRO, Renato Alejandro BAUER, Michael Gregory BELL, Qi CHEN, Graham Robert CUMMING, Todd FIELDS, Douglas Linn GERNERT, Joseph Daniel HO, Talbi Abelkader KAOUDI, Thierry Jean MASQUELIN, Jose Miguel MINGUEZ ORTEGA, Julian PRIEGO SOLER, Antonio RODRIGUEZ HERGUETA, Eric Michael WOERLY
  • GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
    Publication number: 20230250092
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: March 31, 2023
    Publication date: August 10, 2023
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • Glucagon-like peptide1 receptor agonists
    Patent number: 11655242
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 23, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Todd Fields, Joseph Daniel Ho, Fucheng Qu
  • GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
    Publication number: 20200407347
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 31, 2020
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • Urea compounds
    Patent number: 9145437
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 29, 2015
    Assignee: Eli Lilly and Company
    Inventor: Todd Fields
  • Urea compounds
    Patent number: 9145435
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: September 29, 2015
    Assignee: Eli Lilly and Company
    Inventor: Todd Fields
  • NOVEL UREA COMPOUNDS
    Publication number: 20150126469
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 28, 2014
    Publication date: May 7, 2015
    Inventor: Todd FIELDS
  • NOVEL UREA COMPOUNDS
    Publication number: 20150111846
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 23, 2015
    Inventor: Todd FIELDS
  • Compounds and method for treating dyslipidemia
    Patent number: 7786108
    Abstract: Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: August 31, 2010
    Assignee: Eli Lilly and Company
    Inventors: Xinchao Chen, Todd Fields, Nathan Bryan Mantlo, Xiaodong Wang
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20100204207
    Abstract: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: April 20, 2010
    Publication date: August 12, 2010
    Inventors: Xinchao Chen, Christopher Lawrence Cioffi, Sean Richard Dinn, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Saravanan Parthasarathy, Xiaodong Wang
  • Compounds and methods for treating dislipidemia
    Patent number: 7749992
    Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Douglas Linn Gernert, Christopher Lawrence Cioffi, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Compounds And Methods For Treating Dislipidemia
    Publication number: 20070254869
    Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
    Type: Application
    Filed: October 7, 2004
    Publication date: November 1, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Guoqing Cao, Ana Escribano, Maria Fernandez, Todd Fields, Douglas Gernert, Christopher Cioffi, Robert Herr, Nathan Mantlo, Eva Martin De La Nava, Ana Mateo Herranz, Daniel Mayhugh, Xiaodong Wang
  • Compounds and Method for Treating Dyslipidemia
    Publication number: 20070244095
    Abstract: Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: June 23, 2005
    Publication date: October 18, 2007
    Inventors: Xinchao Chen, Christopher Cioffi, Sean Dinn, Ana Escribano, Maria Fernandez, Todd Fields, Robert Herr, Nathan Mantlo, Eva Martin De La Nava, Ana Mateo-Herranz, Saravanan Parthasarathy, Xiaodong Wang